PharmacoEconomics

, Volume 28, Issue 10, pp 923–930

Comparative Effectiveness, Personalized Medicine and Innovation

The Path Forward
  • Adrian Thomas
  • Audrey Phillips
  • Robert Donnelly
  • Catherine Tak Piech
Industry Perspectives Comparative Effectiveness and Personalized Medicine

References

  1. 1.
    The American Recovery and Reinvestment Act of 2009, HR1, 111th Cong.Google Scholar
  2. 2.
    Patient Protection and Affordable Care Act of 2010, HR3590, 111th Cong.Google Scholar
  3. 3.
    US Department of Health and Human Services. Federal Coordinating Council for Comparative Effectiveness Research. Report to the President and Congress, June 30, 2009. Washington, DC: US Department of Health and Human Services, 2009 [online]. Available from URL: http://www.hhs.gov/recovery/programs/cer/cerannualrpt.pdf [Accessed 2010 June 23]Google Scholar
  4. 4.
    US Department of Health and Human Services. Federal Coordinating Council for Comparative Effectiveness Research. Report to the President and Congress, June 30, 2009. Washington, DC: US Department of Health and Human Services, 2009 [online]. Available from URL: http://www.hhs.gov/recovery/programs/cer/cerannualrpt.pdf [Accessed 2010 June 23]Google Scholar
  5. 5.
    Garber A, Tunis S. Does comparative-effectiveness research threaten personalized medicine? [editorial]. N Engl J Med 2009 May 7; 360 (19): 1925–7PubMedCrossRefGoogle Scholar
  6. 6.
    Garrison L, Finley Austin MJ. Linking pharmacogeneticsbased diagnostics and drugs for personalized medicine. Health Aff (Millwood) 2006 Sept/Oct; 25 (5): 1281–90CrossRefGoogle Scholar
  7. 7.
    Of NICE and men. Wall Street J 2010 July 7: A14Google Scholar
  8. 8.
    Peel DC. Your medical records aren’t safe. Wall Street J 2010 Mar 13 [online]. Available from URL: http://online.wsj.com/article/SB10001424052748703580904575132111888664060.html [Accessed 2010 June 23]Google Scholar
  9. 9.
    The Genetic Information Nondiscrimination Act of 2008, Pub.L. 110-233, 110th Cong.Google Scholar
  10. 10.
    Buto K, Juhn P. Can a center for comparative effectiveness information succeed? Perspectives from a health care company. Health Aff 2006 Nov/Dec; 25 (6): w586–8Google Scholar
  11. 11.
    Human genome project information [online]. Available from URL: http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml [Accessed 2010 Jun 17]
  12. 12.
    National Institute of General Medical Sciences. Pharmacogenetics Research Network [online]. Available from URL: http://www.nigms.nih.gov/Initiatives/PGRN [Accessed 2010 Jun 17]Google Scholar
  13. 13.
    Pharm GKB. International Warfarin Pharmacogenetics Consortium [online]. Available from URL: http://www.pharmgkb.org/views/project.jsp?pId=56 [Accessed 2010 Jun 17]Google Scholar
  14. 14.
    International Serious Adverse Events Consortium [online]. Available from URL: http://www.saeconsortium.org/ [Accessed 2010 Jun 17]
  15. 15.
    Foundation for the National Institutes of Health. Biomarkers Consortium [online]. Available from URL: http://www.biomarkersconsortium.org/ [Accessed 2010 Jun 17]Google Scholar
  16. 16.
    Nelson GD. Perspective: preserving the milieu for medical innovation. Health Aff 1994; 13 (3): 112–4CrossRefGoogle Scholar
  17. 17.
    Gelijns A, Rosenberg N. The dynamics of technological change in medicine. Health Aff 1994; 13 (3): 28–46CrossRefGoogle Scholar
  18. 18.
    Phillips A. Looking backward to go forward. Next Generation Pharmaceutical 2009 Apr; 16 [online]. Available from URL: http://www.ngpharma.com/article/Looking-Backwardto-Go-Forward/ [Accessed 2010 Mar 4]Google Scholar
  19. 19.
    Meckley LM, Neumann PJ. Personalized medicine: factors influencing reimbursement. Health Policy 2010 Feb; 94 (2): 91–100PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Adrian Thomas
    • 1
  • Audrey Phillips
    • 2
  • Robert Donnelly
    • 3
  • Catherine Tak Piech
    • 4
  1. 1.Market Access, Johnson & Johnson Pharmaceutical Services LLCRaritanUSA
  2. 2.Biopharmaceutical Public Policy and AdvocacyJohnson & Johnson Government Affairs and PolicyWashington, DCUSA
  3. 3.Health PolicyJohnson & JohnsonWashington, DCUSA
  4. 4.Health Economics and Outcomes ResearchCentocor Ortho Biotech Services LLCTitusvilleUSA
  5. 5.Johnson & JohnsonHorshamUSA

Personalised recommendations